Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 15365146.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma. The genotype of the tumors was assessed with fluorescent in situ hybridization with locus specific probes for the region 1p36. Four of the 24 patients responded (17%). Fifty percent of patients were still free from progression at 6 months and 21% were free from progression at 12 months. Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Brain Neoplasms
- Dacarbazine
- Oligodendroglioma
- Salvage Therapy